7.27
Profound Medical Corp stock is traded at $7.27, with a volume of 150.88K.
It is up +8.51% in the last 24 hours and up +13.06% over the past month.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
See More
Previous Close:
$6.70
Open:
$6.77
24h Volume:
150.88K
Relative Volume:
0.74
Market Cap:
$263.85M
Revenue:
$16.10M
Net Income/Loss:
$-42.57M
P/E Ratio:
-5.1549
EPS:
-1.4103
Net Cash Flow:
$-38.53M
1W Performance:
+8.51%
1M Performance:
+13.06%
6M Performance:
+24.06%
1Y Performance:
+32.91%
Profound Medical Corp Stock (PROF) Company Profile
Name
Profound Medical Corp
Sector
Industry
Phone
647-476-1350
Address
2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON
Compare PROF vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PROF
Profound Medical Corp
|
7.27 | 243.17M | 16.10M | -42.57M | -38.53M | -1.4103 |
|
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Profound Medical Corp Stock (PROF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | Lake Street | Buy |
| Jul-16-24 | Upgrade | Stifel | Hold → Buy |
| Nov-28-23 | Initiated | Stifel | Hold |
| Aug-04-23 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-21-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-15-20 | Initiated | Jefferies | Buy |
View All
Profound Medical Corp Stock (PROF) Latest News
Profound Medical (PROF) price target decreased by 26.77% to 8.49 - MSN
Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future - Yahoo Finance
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: R - GuruFocus
MSN Money - MSN
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics - Benzinga
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics - Sahm
Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference - Yahoo Finance
Profound Medical (TSX:PRN) Stock Price & News - The Motley Fool Canada
Responsive Playbooks and the PROF Inflection - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp.PROF - FinancialContent
Profound Medical : Investor Presentation (Profound Investor Presentation April 2026 ver9final) - marketscreener.com
Profound Medical : Investor Presentation (Profound Investor Presentation April 2026 ver8final) - marketscreener.com
Profound Medical to Release First Quarter 2026 Financial Results on May 7Conference Call to Follow - Investing News Network
Profound Medical : FY 2025 Management Information Circular - marketscreener.com
Profound Medical Schedules First-Quarter 2026 Earnings Release - TipRanks
Profound Medical to report Q1 2026 results May 7, conference call at 4:30 p.m. ET - TradingView
Profound Medical (NASDAQ: PROF) to report Q1 2026 results, host call May 7 - Stock Titan
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow - Toronto Star
Profound Medical (PROF) Stock: Momentum Signals (Smart Money Active) 2026-04-15Community Sell Signals - UBND thành phố Hải Phòng
PROF SEC FilingsProfound Med Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Profound Medical Corp. - Mena FN
Stocks in play: Profound Medical Corp. - The Globe and Mail
Profound Medical to Present Business Update at Conference - TipRanks
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference - The Manila Times
Profound Medical (NASDAQ: PROF) plans business update at 2026 Bloom Burton healthcare investor conference - Stock Titan
Income Plays: Is Profound Medical Corp trading at a discountRisk Management & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Analyst Calls: Is Profound Medical Corp showing insider buying2026 Technicals & Expert-Curated Trade Recommendations - baoquankhu1.vn
Buy Signal: Is Profound Medical Corp in a bullish channel2026 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn
Understanding the Setup: (PROF) and Scalable Risk - Stock Traders Daily
If You Invested $1,000 in Profound Med Corp (PROF) - Stock Titan
Rate Cut: What hedge funds are buying Profound Medical Corp2026 Gainers & AI Driven Price Predictions - baoquankhu1.vn
Profound Medical Corp. Investigated by the Portnoy Law Firm - GlobeNewswire
Should I Buy Profound Medical (PROF) Stock Today | Price at $6.42, Down 1.08%Stock Community Signals - Newser
Short Squeeze: Can Profound Medical Corp sustain its profitability2026 Top Gainers & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Forecast Cut: Is Profound Medical Corp being accumulated by smart moneyGlobal Markets & AI Powered Market Entry Strategies - baoquankhu1.vn
Will Profound Medical (PROF) Stock Beat Expectations | Price at $6.85, Up 6.53%Real Trader Insights - Newser
Insider Buying: Profound Medical (TSE:PRN) Director Acquires 20,000 Shares of Stock - MarketBeat
Profound Medical Showcases TULSA-PRO at Key Radiology Meeting - TipRanks
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting - Bitget
Profound Medical’s TULSA-PRO® Incision-Free, MRI-Guided Prostate Treatment Highlighted at 2026 Society of Interventional Radiology Meeting - Minichart
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting - Investing News Network
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting - The Manila Times
Profound Medical: TULSA-PRO highlighted in multiple presentations at SIR 2026 - TradingView
TULSA-PRO showcased at SIR 2026 for Profound Medical (NASDAQ: PROF) - Stock Titan
Incision-free prostate treatment lands 7 talks at April medical meeting - Stock Titan
PROF Technical Analysis & Stock Price Forecast - Intellectia AI
Short Interest in Profound Medical (NASDAQ:PROF) Expands By 19.8% - marketbeat.com
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure Milestone - MarketScreener
Profound Medical (NASDAQ:PROF) Trading Down 1.7%Time to Sell? - marketbeat.com
Profound Medical (TSE:PRN) Stock Price Down 2.6%Time to Sell? - MarketBeat
Income Plays: Is Profound Medical Corp showing insider buyingStop Loss & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Profound Medical Corp Stock (PROF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):